Welcome to Amayeza Information Centre
We are an independant medicine information centre that aims to provide reliable, accurate, objective, and up-to-date information on medicine to pharmacists and other health care professionals across South Africa.
The word “Amayeza” means “Medicine” in the Xhosa language.
Please take note that our drug information service is only available to subscribers to Amayeza. This has been in effect from 1st April 2013. In order to benefit from our medicine information service, you will need to subscribe to us.
2015 – Flu season
The ‘flu season is almost upon us. The influenza vaccine has been made available in the past week. This is later than in previous years where influenza vaccine has been available from health facilities and pharmacies as early as March. The reason for the delay in influenza vaccine availability is as follows. There has been change (drift) in influenza viruses circulating during the 2014 influenza season, therefore the influenza strains included in the 2015/2016 influenza vaccines had to be changed from the strains used in previous years. This change in strains has resulted in delays in manufacturing and quality control of the 2015 southern hemisphere vaccine globally. This has led to a delay in delivery and availability of the vaccine.
The delay in vaccine availability does not mean that it will be too late to give the vaccine. It does mean however, that once vaccine is available, health workers are should alert their patients of vaccine availability and encourage them to come in for vaccination.
Groups recommended for influenza vaccination include:
- Pregnant women irrespective of stage of pregnancy, or postpartum (within 2 weeks after delivery)
- Persons (adults or children) who are at high risk for influenza and its complications because of underlying medical conditions and who are receiving regular medical care for conditions such as chronic pulmonary (including tuberculosis) and cardiac diseases, chronic renal diseases, diabetes mellitus and similar metabolic disorders, individuals who are immunosuppressed (including HIV infected persons with CD4 counts >100 cells/μl), and individuals who are morbidly obese (body mass index ≥40 kg/m2)
- Healthcare workers
- Residents of old-age homes and chronic care and rehabilitation institutions
- Persons over the age of 65 years
- Children aged 6 months – 59 months
- Persons aged 6 months to ≤18 years on long-term aspirin therapy
- Adults and children who are family contacts of high-risk cases
- Any persons wishing to minimise the risk of influenza acquisition, especially in industrial settings, where large-scale absenteeism could cause significant economic losses.
It is important to remember that it takes about two weeks from time of vaccination for a protective antibody response to develop, therefore individuals for whom influenza vaccination is recommended should be encouraged to access the vaccine as soon as it is available.
Reference: The National Institute for Communicable Disease
EBOLA OUTBREAK – USEFUL INFORMATION
|Ebola Virus Disease PDF Download|
|Ebola virus disease||Previously known as Ebola haemorrhagic fever.Caused by a virus (filovirus).The disease is severe and often fatal in humans and primates (such as monkeys, gorillas and chimpanzees).|
|Outbreaks||Sporadic outbreaks have occurred since 1976 in the Democratic Republic of Congo, Uganda, South Sudan, Congo and Gabon.Current (2014) outbreak in Guinea, Liberia, Sierra Leone and Nigeria.|
|Transmission||Spread via direct contact with contaminated blood or secretions of an infected person or animal (dead or alive), and indirectly via contact with objects (such as needles, clothing and bedding) contaminated with infectious secretions.Does not spread through the air and cannot be transmitted by mosquitoes.|
|High risk groups||Healthcare workers, family members or friends in close contact with infected people.Hunters/other persons who may come into contact with infected animals.|
|Incubation period||Symptoms start 2 to 21 days (average 8-10 days) after exposure.|
|Symptoms||Fever, diarrhoea, vomiting, stomach pain, lack of appetite, weakness, headache, joint and muscle aches, rash, sore throat, chest pains, red eyes, hiccups, difficulty in breathing and swallowing, impaired kidney and liver function as well as bleeding inside and outside of the body.|
|Treatment||Treatment is typically supportive|
|Prevention||There is no vaccine available to prevent the disease|
|Travellers||Travellers to endemic areas, under normal circumstances, are at low risk but they should adhere to preventative measures and seek medical attention if any related symptoms appear and mention their travel history to the doctor before the consultation.|
|Preventative measures||During an outbreak, strict measures must be taken to prevent the disease from spreading, especially in high risk groups:
About Ebola hemorrhagic Fever. CDC [homepage on the internet]. Available from: http://www.cdc.gov/vhf/ebola/about.html.
- Ebola Virus Disease: Frequently asked Questions. National Institute for communicable diseases. Available from: http://www.nicd.ac.za/?page=alerts&id=5&rid=359
- National health services. Available from www.travax.co.za
- Ebola virus disease. WHO. Fact sheep No 103. Last updated April 2014. Available from: http://www.who.int/mediacentre/factsheets/fs103/en/
Please click on the link below to view and download the 2015 Childhood immunisation schedule:
South African Society of Travel Medicine (SASTM) Publications:
The following two publications related to travel medicines and vaccines are available via the SASTM website.
Beyond Childhood Vaccination
A Guide to the Practice of Travel Medicine
Last updated: 25 April 2015
Data Privacy Statement
Amayeza Information Services stores any personal information to enable us to address the enquiry, or other such matters that have been raised, and to document our response. The information will be retained in a secure server and will only be used for this purpose, unless required for legal proceedings. If reporting an adverse event, the information provided will be used in order to meet regulatory requirements in relation to the safety of medicines. In accordance with applicable law, you may have a right to access and correct your information. If you would prefer that Amayeza does not store your personal data, please let us know.